Pfizer asks FDA to authorize its booster for 16-17 year olds
Pfizer yesterday asked the Food and Drug Administration to expand the emergency use authorization for its COVID-19 vaccine booster to include youth aged 16 and 17.
“It is our hope to provide strong protection for as many people as possible, particularly in light of the new variant,” tweeted Pfizer CEO Albert Bourla.
FDA last month authorized, and the Centers for Disease Control and Prevention recommends (https://www.cdc.gov/media/releases/2021/s1119-booster-shots.html), a single booster dose of the Pfizer or Moderna COVID-19 vaccine for all individuals aged 18 or older at least six months after receiving the initial two-dose series or two months after receiving the single-dose Johnson & Johnson vaccine.
Related News Articles
Headline
Adults age 65 and older are encouraged to receive an updated dosage of the COVID-19 vaccine, the Centers for Disease Control and Prevention announced April 25…
Headline
The Pfizer and Moderna COVID-19 vaccines can cause myocarditis, but do not appear to cause infertility, Guillain-Barré syndrome, Bell’s palsy, thrombosis with…
Headline
Centers for Disease Control and Prevention Director Mandy Cohen, M.D., Feb. 28 endorsed a recommendation by its Advisory Committee on Immunization Practices…
Headline
A CDC study released Dec. 21 found low COVID-19 and flu vaccination coverage for most adults, and low RSV vaccination coverage for adults aged 60 and…
Headline
Fewer than one in four health care professionals working in acute care hospitals and nursing homes were up to date with COVID-19 vaccination during the 2022-23…
Headline
Children under age 12 should receive a 0.25 milliliter dose of the 2023-24 Moderna COVID-19 vaccine, not the full vial for that age group, the Food and Drug…